Phytochemical Name : Citrus aurantifolia extract

Properties Information
PhytoCAT-ID PhytoCAT-1849
Phytochemical name or plant extracts Citrus aurantifolia extract
PMID 25276192
Literature evidence New approach of breast cancer therapy is developed toward combination therapy with agents that have a specific molecular target.
IUPAC name NA
Phytochemicals’ class or type of plant extracts Ethanolic extract
Source of phytochemicals or plant Extracts Citrus aurantifolia
Geographical availability Introduced to : Angola, Assam, Bangladesh, Belize, Benin, Bolivia, Cambodia, Caroline Is., Cayman Is., Central American Pac, Chad, Christmas I., Cook Is., Costa Rica, Cuba, Dominican Republic, East Himalaya, El Salvador, Ethiopia, Fiji, Florida, Galápagos, Gambia, Gilbert Is., Guinea-Bissau, Gulf of Guinea Is., Haiti, India, Laos, Line Is., Malaya, Marianas, Marshall Is., New Caledonia, Niger, Niue, Oman, Pakistan, Puerto Rico, Sri Lanka, Trinidad-Tobago, Tuamotu, Venezuela, Vietnam, Windward Is.
Plant parts Peels
Other cancers Breast cancer
Target gene or protein p53, Bcl-2
Gene or Protein evidence Evidence of apoptosis and protein expression of p53 and Bcl-2 indicated that both single applications and combinations of CPE and doxorubicin are able to increase apoptotic bodies of MCF-7 cells by increasing the proteins expression.
Target pathways PI3K/Akt pathway
IC50 59 μg/mL against MCF-7
Potency This result suggested that CPE could perform as co-chemotherapeutic agent with doxorubicin on breast cancer cells.
Cell line/ mice model MCF-7
Additional information  The result showed that CPE 6 μg/mL induced apoptosis and cell accumulation at G1 phase, while CPE 15 μg/mL induced apoptosis and cell accumulation at G2/M phase. The combination of doxorubicin 200 nM with CPE 6 μg/mL increased apoptosis induction than their single treatment, and cell accumulation at G2/M phase.
PubChem ID NA
Additional PMIDs 12222671 25276192
Additional sources of information https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:59599-2
Safety NA